Voyager Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Voyager Therapeutics' es Al Sandrock , nombrado en Mar 2022, tiene una permanencia de 2.42 años. compensación anual total es $3.17M, compuesta por 19.7% salario y 80.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de $431.70K. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 5.2 años, respectivamente.
Información clave
Al Sandrock
Chief Executive Officer (CEO)
US$3.2m
Compensación total
| Porcentaje del salario del CEO | 19.7% |
| Permanencia del CEO | 2.5yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 2yrs |
| Promedio de permanencia en la Junta Directiva | 4.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Aug 26Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Looking Back In On Voyager Therapeutics
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
May 12Voyager Does A Reboot After First Generation Failures
Mar 25Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Feb 07Voyager Therapeutics: Another Year, Another Deal
Nov 21Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | -US$3m |
| Dec 31 2023 | US$3m | US$624k | US$132m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$96m |
| Mar 31 2023 | n/a | n/a | US$99m |
| Dec 31 2022 | US$7m | US$525k | -US$46m |
Compensación vs. Mercado: La compensación total de Al($USD3.17M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.43M).
Compensación vs. Ingresos: La compensación de Al ha sido consistente con los resultados de la empresa en el último año.
CEO
Al Sandrock (66 yo)
2.5yrs
Permanencia
US$3,172,433
Compensación
Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He served as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.5yrs | US$3.17m | 0.12% $ 367.6k | |
| COO & Acting Chief Business Officer | no data | US$1.38m | 0.062% $ 197.0k | |
| Chief Legal Officer | 1.2yrs | US$1.91m | 0% $ 0 | |
| Founder | no data | sin datos | sin datos | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Chief Scientific Officer | 2yrs | sin datos | 0.16% $ 512.6k | |
| Chief Human Resources Officer | 4yrs | sin datos | sin datos | |
| Chief Corporate Affairs Officer & Chief of Staff to the CEO | 2.7yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos |
2.0yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VYGR se considera experimentado (2.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.6yrs | US$3.17m | 0.12% $ 367.6k | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Consultant & Member of Scientific Advisory Board | 5.3yrs | US$1.81m | sin datos | |
| Independent Director | 10.7yrs | US$263.78k | 0.10% $ 319.3k | |
| Independent Director | 7.7yrs | US$248.78k | 0.040% $ 127.4k | |
| Independent Director | 9yrs | US$255.78k | 0% $ 0 | |
| Independent Chairman of the Board | 9.2yrs | US$281.28k | 0.057% $ 183.2k | |
| Independent Director | 2.2yrs | US$250.78k | 0% $ 0 | |
| Director | 1.6yrs | US$452.32k | 0.0053% $ 17.0k | |
| Independent Director | 1.7yrs | US$432.23k | 0% $ 0 | |
| Independent Director | 4yrs | US$255.28k | 0% $ 0 |
4.6yrs
Permanencia media
64.5yo
Promedio de edad
Junta con experiencia: La junta directiva de VYGR se considera experimentada (5.2 años de antigüedad promedio).